Delcath Systems Inc DCTH:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
4.36quote price arrow up+0.10 (+2.35%)
Volume
7,518
52 week range
3.49 - 11.95
Loading...
  • Open4.26
  • Day High4.40
  • Day Low4.26
  • Prev Close4.26
  • 52 Week High11.95
  • 52 Week High Date11/08/21
  • 52 Week Low3.49
  • 52 Week Low Date06/17/22

Key Stats

  • Market Cap37.50M
  • Shares Out8.60M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-43.74

KEY STATS

  • Open4.26
  • Day High4.40
  • Day Low4.26
  • Prev Close4.26
  • 52 Week High11.95
  • 52 Week High Date11/08/21
  • 52 Week Low3.49
  • 52 Week Low Date06/17/22
  • Market Cap37.50M
  • Shares Out8.60M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change-43.74

RATIOS/PROFITABILITY

  • EPS (TTM)-3.80
  • P/E (TTM)-1.15
  • Fwd P/E (NTM)-1.30
  • EBITDA (TTM)-27.747M
  • ROE (TTM)-492.68%
  • Revenue (TTM)3.81M
  • Gross Margin (TTM)85.02%
  • Net Margin (TTM)-797.16%
  • Debt To Equity (MRQ)-565.71%

EVENTS

  • Earnings Date11/07/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Delcath Systems Inc

There is no recent news for this security.

Profile

MORE
Delcath Systems, Inc. is an interventional oncology company, which is focused on the treatment of primary and metastatic liver cancers. The Company's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical...
Roger Stoll Ph.D.
Non-Executive Independent Chairman of the Board
Gerard Michel
Chief Executive Officer, Director
John Purpura
Chief Operating Officer, Executive Vice President - Global Head of Operations
Anthony Dias CPA
Vice President - Finance
Address
1633 Broadway Ste 22C
New York, NY
10019-6708
United States

Top Peers

SYMBOLLASTCHG%CHG
POAI
Predictive Oncology Inc
0.4689+0.0304+6.93%
MBOT
Microbot Medical Inc
5.22+0.21+4.19%
TLIS
Talis Biomedical Corp
0.7701+0.0191+2.54%
INVO
INVO Bioscience Inc
1.03-0.02-1.95%
QLGN
Qualigen Therapeutics Inc
0.425+0.009+2.16%